Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Cheung
    Cheung
  8. Voss
    Voss
  9. O'Reilly
    O'Reilly
  10. Robson
    Robson

Groups

  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)
  7. Epidemiology and Biostatistics (151)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Survivorship Research (121)
  10. Surgery (118)
Search Within
Formats
  1. Journal Article (745)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (10)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Roberta Zappasodi (24)

More People

Years
  1. 2025 (28)
  2. 2024 (63)
  3. 2023 (45)
  4. 2022 (123)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (404)
  2. Breast Cancer Research (67)
  3. BMC Cancer (64)
  4. Genome Biology (46)
  5. Journal of Hematology & Oncology (42)
  6. Journal of Translational Medicine (35)

More Publications

Results (1085)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Exploratory platform trial to evaluate immunotherapy combinations with chemotherapy for the treatment of patients with previously untreated metastatic pancreatic adenocarcinoma (REVOLUTION)
    Meeting Abstract

    Lyman, J.; O'Reilly, E.; Wainberg, Z.; Fisher, G.; Wolff, R.; Ko, A.; O'Hara, M.; Singh, H.; Amaravadi, R.; Kimmelman, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from the JAVELIN Merkel 200 trial
    Meeting Abstract

    D'Angelo, S.; Lebbé, C.; Mortier, L.; Brohl, A.; Fazio, N.; Grob, J. J.; Prinzi, N.; Hanna, G.; Hassel, J.; Kiecker, F.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • KEYNOTE-495/KeyImPaCT: Updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer
    Meeting Abstract

    Herbst, R.; Lam, W. S.; Hellmann, M.; Gubens, M.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J.; Lee, J. S.; Yang, N. C. H.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant/refractory (R/R) melanoma
    Meeting Abstract

    Shoushtari, A.; Ottesen, L.; Levitsky, V.; Hansen, T. B.; Hornyak, T.; Olszanski, A.; Nyakas, M.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIS)
    Meeting Abstract

    Georgina Long, A. O.; Tang, T.; Apfel, A.; Paulucci, D.; Chasalow, S.; Tenney, D.; Fusaro, G.; Schadendorf, D.; Tawbi, H.; Hodi, F. S.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression
    Meeting Abstract

    Klohe, E.; Suchindran, S.; Kapoor, G.; D'Souza, J.; Corigleano, E.; Araujo, D.; D'Angelo, S.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS)
    Meeting Abstract

    Kapoor, G.; Zajic, S.; Suchindran, S.; Kim, J.; Saxena, U.; Bhaskar, A.; Kaczynski, H.; Nathenson, M.; D'Souza, J.; Rich, B.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab
    Meeting Abstract

    Sanborn, R.; Gabrail, N.; Carneiro, B.; O'Hara, M.; Bordoni, R.; Gordon, M.; Khalil, D.; Hauke, R.; Taglienti, C.; Rogalski, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Durvalumab (D) ± tremelimumab (T) + platinumetoposide (EP) in extensive-stage small-cell lung cancer (ES–SCLC): RNA sequencing analysis to explore canonical markers of IO activity in CASPIAN
    Meeting Abstract

    Xie, M.; Chugh, P.; O'Brien, C.; Lai, Z.; Stewart, R.; Paz-Ares, L.; Goldman, J.; Garassino, M.; Rudin, C.; Barrett, J. C.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: Part 1 results
    Meeting Abstract

    Friedman, C.; Carvajal, R.; Davar, D.; Castanon, E.; Ascierto, P.; Calvo, E.; O'Hara, M.; Powell, S.; Shapira-Frommer, R.; Garralda, E.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save